Persulfidation of transcription factor FOXO1 at cysteine 457: A novel mechanism by which H2S inhibits vascular smooth muscle cell proliferation

Xiaoyu Tian,Dan Zhou,Yong Zhang,Yunjia Song,Qingyou Zhang,Dingfang Bu,Yan Sun,Liling Wu,Yuan Long,Chaoshu Tang,Junbao Du,Yaqian Huang,Hongfang Jin
DOI: https://doi.org/10.1016/j.jare.2020.06.023
IF: 12.822
2021-01-01
Journal of Advanced Research
Abstract:FOXO1 is involved in the inhibitory effect of H<sub>2</sub>S on vascular smooth muscle cell proliferation.H<sub>2</sub>S inhibits vascular smooth muscle cell proliferation by maintaining FOXO1 activity.H<sub>2</sub>S preserves FOXO1 activity by persulfidation.H<sub>2</sub>S persulfidates FOXO1 at Cys457 and subsequently prevents FOXO1 phosphorylation at Ser256.The results provide new ideas for therapeutic strategies for anti-vascular remodeling.The mechanisms of vascular smooth muscle cell (VSMC) proliferation have not been fully clear. This study aimed to explore whether hydrogen sulfide (H<sub>2</sub>S) persulfidates the transcription factor FOXO1 to inhibit VSMC proliferation. After the proliferation of VSMC A7r5 cells was induced by endothelin-1 (ET-1), FOXO1 phosphorylation and proliferating cell nuclear antigen (PCNA) expression were detected by Western blotting, the degree of FOXO1 nuclear exclusion and PCNA fluorescent signals in the nucleus were detected by immunofluorescence, and the persulfidation of FOXO1 was measured through a biotin switch assay. The results showed that ET-1 stimulation increased cell proliferation, FOXO1 phosphorylation and FOXO1 nuclear exclusion to the cytoplasm in the cells. However, pretreatment with NaHS, an H<sub>2</sub>S donor, successfully abolished the ET-1-induced increases in the VSMC proliferation, FOXO1 phosphorylation, and FOXO1 nuclear exclusion to the cytoplasm. Mechanistically, H<sub>2</sub>S persulfidated the FOXO1 protein in A7r5 and 293T cells, and the thiol reductant DTT reversed this effect. Furthermore, the C457S mutation of FOXO1 abolished the H<sub>2</sub>S-induced persulfidation of FOXO1 in the cells and the subsequent inhibitory effects on FOXO1 phosphorylation at Ser256, FOXO1 nuclear exclusion to the cytoplasm and cell proliferation. Thus, our findings demonstrated that H<sub>2</sub>S might inhibit VSMC proliferation by persulfidating FOXO1 at Cys457 and subsequently preventing FOXO1 phosphorylation at Ser256.Schematic diagram of the mechanism by which H<sub>2</sub>S inhibits VSMC proliferation targeting on the FOXO1. H<sub>2</sub>S persulfidates FOXO1 at Cys457, which reduces FOXO1 phosphorylation at Ser256, prevents the FOXO1 nucleus exclusion to the cytoplasm, and further protecting against ET-1-induced VSMC proliferation.<span class="display"><span><ol class="links-for-figure"><li><a class="anchor download-link u-font-sans" href="https://ars.els-cdn.com/content/image/1-s2.0-S2090123220301326-ga1_lrg.jpg"><span class="anchor-text">Download : <span class="download-link-title">Download high-res image (180KB)</span></span></a></li><li><a class="anchor download-link u-font-sans" href="https://ars.els-cdn.com/content/image/1-s2.0-S2090123220301326-ga1.jpg"><span class="anchor-text">Download : <span class="download-link-title">Download full-size image</span></span></a></li></ol></span></span>
multidisciplinary sciences
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to explore how hydrogen sulfide (H₂S) inhibits the proliferation of vascular smooth muscle cells (VSMC) through specific mechanisms. Specifically, the researchers are concerned with whether H₂S inhibits the proliferation of VSMC by sulfhydrylating the transcription factor FOXO1 at cysteine 457 (Cys457). This process may prevent the phosphorylation of FOXO1 at serine 256 (Ser256), thereby maintaining the active state and nuclear localization of FOXO1, and ultimately achieving the effect of inhibiting cell proliferation. The research results not only reveal a new mechanism of H₂S in the regulation of cardiovascular homeostasis, but also provide new ideas and targets for the treatment of vascular remodeling diseases.